【摘要】 目的 分析异基因造血干细胞移植术（allogeneic hematopoietic stem cell transplantation，allo-HSCT）后并发毛细血管渗漏综合征（capillary leak syndrome，CLS）的发生率、危险因素和结局，并探讨其防治措施。 方法 回顾性分析2005年6月-2011年2月住院的allo-HSCT术后14例并发CLS的临床资料。 结果 CLS发生率为9.2%（14/152）。年龄、性别、诊断、HLA配型、预处理、CD34+细胞量、粒细胞集落刺激因子（granulocyte colony-stimulating factor，G-CSF）用量、植入时间均不能认定为造血干细胞移植后CLS诱发因素。 结论 HSCT术后CLS诱因尚不清楚，采用限水、减量G-CSF、使用糖皮质激素和羟乙基淀粉等措施及时治疗，有助于控制CLS。【Abstract】 Objective To study the occurrence rate, risk factors and outcomes of capillary leak syndrome (CLS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and discuss its prevention and treatment. Methods We retrospectively analyzed the clinical records of 14 allo-HSCT recipients complicated with CLS from June 2005 to February 2011. Results Fourteen out of 152 patients developed CLS with a cumulative incidence of 9.2 %. None of the 8 clinical parameters including age, gender, underlying disease, donor type, conditioning regimen, CD34+ cell dose, granulocyte colony-stimulating factor (G-CSF) dosage, and days to neutrophil engraftment could be identified as risk factors for the occurrence of CLS. Conclusions Risk factors for CLS after allo-HSCT have not been fully established. Restriction of water intake, administration of corticosteroids and hydroxyethyl starch can be beneficial for patients with CLS.
【摘要】 目的 观察聚明胶肽注射液和羟乙基淀粉（130/0.4）氯化钠注射液对创伤失血性休克患者的临床治疗效果。 方法 将2006年6月-2008年10月创伤失血性休克患者32例随机分为聚明胶肽组和羟乙基淀粉组，每组16例。抢救时除采用止血、扩容、纠酸等综合措施外，分别输入聚明胶肽注射液和羟乙基淀粉（130/0.4）氯化钠注射液1 500 mL。两组均监测血压、尿量和血气分析指标，比较两组指标恢复正常以及所需的时间。 结果 聚明胶肽组与羟乙基淀粉组上述指标恢复正常及所需的时间无差异，两组生存率、致残率及并发症均无差异。 结论 聚明胶肽注射液用于创伤失血性休克的疗效与羟乙基淀粉（130/0.4）氯化钠注射液相当。【Abstract】 Objective To observe the clinical effects of polygeline injection and hydroxyethyl starch(130/0.4) NaCl injection (HES)on the traumatic hemorrhagic shock. Methods A total of 32 patients with traumatic hemorrhagic shock were randomly divided into polygeline injection group and HES group,with 16 patients in each. The same measures such as hemstasis, expanding blood volume, correction of acid base disturbance and so on were adopted in the both groups. The patients in the polygeline injection group and HES group were respectively treated with polygeline injection and HES NaCl injection in a dose of 1500 mL by intravenous infusion. The time from injection to the recovery of BP, urinary output, and blood gas to normal level was recorded. Results BP, urinary output, and blood gas were all improved significantly, there was no significant difference between the two groups (Pgt;0.05). Conclusion The clinical effect of polygeline injection on stabilizing BP and improving microcirculation appears comparable to that of HES.
ObjectiveTo investigate the influence of 6% hydroxyethyl starch (HES, 130/0.4)on blood coagulation of patients after off-pump coronary artery bypass grafting (opCAB)by thromboelastography (TEG). MethodsOne hundred patients undergoing elective opCAB in Department of Cardiovascular Surgery, General Hospital of Shenyang Military Area Command between May and July 2013 were enrolled in this study. All the patients were randomly divided into 2 groups using random number table method with 50 patients in each group. In the experimental group (G1 group), there were 27 males and 23 females with their age of 64.9±4.4 years, who received intravenous 6% HES (130/0.4)20 ml/kg in 4 hours postoperatively. In the control group (G2 group), there were 31 males and 19 females with their age of 63.1±5.8 years, who received intravenous lactated ringers 20 ml/kg in 4 hours postoperatively. After postoperative ICU admission, full blood count, coagulation tests and TEG were examined. Chest and mediastinal drainage was recorded at 6 hours and 24 hours postoperatively. ResultsThere was no statistical difference in chest and mediastinal drainage 24 hours postoperatively between the 2 groups (591.7±171.7 ml vs. 542.4±174.0 ml, P > 0.05). None of the patients received reexploration for bleeding. There was no statistical difference in hemoglobin, hematocrit, platelet count or traditional coagulation index between the 2 groups (P > 0.05). TEG showed no significant change in coagulation time after intravenous fluid infusion in either group. Reaction time was slightly extended in both groups, but there was no statistical difference in reaction time between the 2 groups (P > 0.05). Maximum amplitude (MA)of G1 group was significantly decreased after intravenous fluid infusion (55.9±10.0 mm vs. 62.8±7.9 mm, P < 0.05), but still within the normal range. There was no significant change in MA after intravenous fluid infusion in G2 group. ConclusionIntravenous infusion of 6% HES (130/0.4)20 ml/kg can reduce platelet function and clot strength, but does not significantly increase postoperative chest or mediastinal drainage, or the incidence of postoperative reexploration for bleeding. It's safe to administer 6% HES (130/0.4)for patients after OPCAB.